3 results about "Lipid moiety" patented technology

The present disclosure provides a Lipid-Phosphocholine-Carboxylic Acid Agent being a compound comprising one or more groups, wherein each group is independently selected from Lipid Moiety (LM), Phosphocholine Moiety (PCM), Carboxylic Acid Moiety, Amide Moiety, and Attachment Moiety (AM), and wherein each group is covalently attached, directly or indirectly, to a multivalent linker (i.e., Composition Linker Moiety (CLM)), or pharmaceutically acceptable salts thereof, and related conjugates. The present disclosure also relates to uses of the Lipid-Phosphocholine-Carboxylic Acid Agents and conjugates, e.g., in delivering nucleic acid and / or treating or preventing diseases.

The present application relates to ionizable cationic lipid-mediated pulmonary targeting nucleic acid delivery system and application. Specifically, the present application provides a kind of lipid nanoparticles, the lipid part of the lipid nanoparticles includes ionizable cationic lipid, phospholipid and polyethylene glycol lipid, wherein ionizable cationic lipid includes compound 1, and wherein the content of compound 1 is 80 mol% or more based on the total amount of lipid in the lipid nanoparticle. The lipid nanoparticle significantly improves the lung targeting efficiency and simplifies the formulation design process.

The present invention relates to a lipopeptide building block consisting of(i) a peptide moiety comprising a coiled coil peptide chain segment, wherein said coiled coil peptide chain segment comprises 3 to 8 repeat units, and wherein said repeat unit consists of the sequence IEKKIE-X0 (SEQ ID NO:58), wherein X0 represents an amino acid, and wherein preferably said repeat unit consists of the sequence selected from IEKKIEG (SEQ ID NO:59), IEKKIEA (SEQ ID NO:12) or IEKKIES (SEQ ID NO:13), and wherein further preferably said repeat unit consists of the sequence IEKKIES (SEQ ID NO:13);(ii) a lipid moiety comprising, preferably consisting of, the formula LM-Iwherein R1 and R2 are independently C11-15alkyl, wherein preferably R1 and R2 are independently —C11H23, —C13H27 or —C15H31, and wherein further preferably R1 and R2 are —C15H31; and wherein R3 is hydrogen or —C(O)C11-15alkyl, and wherein preferably R3 is H or —C(O)C15H31;and wherein said lipid moiety is linked to said peptide moiety, wherein the wavy line in formula LM-I indicates the linkage site to said peptide moiety, and wherein preferably said lipid moiety is linked to the N-terminus of said peptide moiety, as well as conjugates comprising said lipopeptide building blocks to which antigens are coupled, bundles of such conjugates, synthetic virus-like particles (SVLPs) comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said conjugates, bundles of conjugates, said SVLPs and said pharmaceutical compositions for use as a medicament, as vaccines and for use in methods of preventing or treating a disease, preferably selected from infectious diseases, allergies and cancer, and generally to efficiently induce antigen specific immune responses.